Myeloma Patients Europe will hold an online webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology that took place in Orlando in December 2015. Continue reading
Elotuzumab receives a positive Committee for Medicinal Products for Human Use (CHMP) opinion for the treatment of multiple myeloma patients who have receive at least one prior therapy.
The reccommensation is based in the results of a randomised open-label Phase 3 study evaluating the use of elotuzumab in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethashone alone. The results show that myeloma progresses more slowly on those patients who took elotuzumab compared to those who didn’t (difference in medians of 4.2 months). Continue reading
The European Medicines Agency is currently inviting one or two myeloma patients to participate in a discussion and oral explanation about a potential medicine to treat the disease during the COMP meeting in January (Committee for Orphan Medical Products).
The discussions relates to an orphan designation for a potential drug to treat multiple myeloma and the patients designated will be able to contribute from a patient perspective. Continue reading
MPE is looking for a finance administrator. Apply for this job offer by sending motivation letter and CV to Ananda Plate plate@mpeurope.org by 28 April 2016. Continue reading
Myeloma Patients Europe will hold an online webinar covering the major advances that have occured in understanding the biology of multiple myeloma and the current approach to its diagnosis based on the latest international guidelines, as well as the benefits of early testing in this pathology. Continue reading
Patient Advocacy sessions were again an integral part of EHA’s annual congress program! PDFs of all three patient advocacy sessions are now available. Click on the respective presentation to download the slides.
We would like to thank CML Advocates Network for putting all together this information and circulating across all the involved groups. Continue reading
Myeloma Patients Europe will hold an online webinar to review the most recent myeloma findings presented at the annual meeting of the European Hematology Association that took place in Vienna in June 2014.
Where is your patient group? Where do you want to get to? How you will get there? Patient organisations usually find several issues when trying to achieve their objectives due to limitations in terms of resources, time or strategy. However, some other are able so overcome these barriers and succeed in their mission. So how are they able to make it? The answer is simple: they have a plan. Continue reading
Myeloma Patients Europe will hold an online webinar on smoldering myeloma and the latest updates in its field of research. The talk will be given by Dr Jens Hillengaß, Haematology and Oncology Deparmtment at the University of Heidelberg (Germany) and Dr Maria Victoria Mateos, Haematology Department at the University Hospital of Salamanca (Spain) Continue reading
Myeloma Patients Europe will hold an online webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology that took place in San Francisco in December 2014. Continue reading